Prescribed anti-glaucoma medication consumption and road traffic crash.
drivers
prescription anti-glaucoma medication
road traffic crash
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
15
11
2022
received:
02
07
2021
accepted:
24
11
2022
medline:
5
4
2023
pubmed:
30
11
2022
entrez:
29
11
2022
Statut:
ppublish
Résumé
Glaucoma is one of the leading causes of visual impairment worldwide. Influence of visual defects associated with this condition, as well as potential side effects of anti-glaucoma medications on driving may be a relevant traffic safety concern. This study therefore aimed to investigate whether and/or to what extent prescribed anti-glaucoma medicine consumption is associated with increased likelihood of crash risk, and traffic crash responsibility among drivers involved in road traffic crashes. Data from three French national databases were extracted and matched as part of the CESIR (a combination of studies on health and road safety) project. The sample included 201 497 drivers involved in an injurious road crash in France from July 1, 2005 to December 31, 2015, and an age- and sex-matched control group (113 357 drivers) that was randomly drawn from the general population. Exposure to anti-glaucoma medications were compared between responsible and non-responsible drivers involved in a crash and between drivers involved in a crash and people from the control group. The proportion of drivers with prescribed anti-glaucoma medicine markedly increased with age. One type (OR = 0.79, 95% CI: 0.72-0.86) and two or more types (OR = 0.82, 95% CI: 0.68-0.98) anti-glaucoma medicine prescriptions were less frequent in crash-involved drivers than in controls. One type (OR = 0.99, 95% CI: 0.88-1.12) and two or more types (OR = 1.04, 95% CI: 0.82-1.33) anti-glaucoma medicine prescriptions were not associated with crash responsibility. Our findings are reassuring as regard to existing guidelines for safe driving for individuals using anti-glaucoma medications. Our results also suggest that driving behavior adaptation is effective mitigating potential traffic crash risks for people diagnosed with glaucoma.
Sections du résumé
BACKGROUND
Glaucoma is one of the leading causes of visual impairment worldwide. Influence of visual defects associated with this condition, as well as potential side effects of anti-glaucoma medications on driving may be a relevant traffic safety concern. This study therefore aimed to investigate whether and/or to what extent prescribed anti-glaucoma medicine consumption is associated with increased likelihood of crash risk, and traffic crash responsibility among drivers involved in road traffic crashes.
METHODS
Data from three French national databases were extracted and matched as part of the CESIR (a combination of studies on health and road safety) project. The sample included 201 497 drivers involved in an injurious road crash in France from July 1, 2005 to December 31, 2015, and an age- and sex-matched control group (113 357 drivers) that was randomly drawn from the general population. Exposure to anti-glaucoma medications were compared between responsible and non-responsible drivers involved in a crash and between drivers involved in a crash and people from the control group.
RESULTS
The proportion of drivers with prescribed anti-glaucoma medicine markedly increased with age. One type (OR = 0.79, 95% CI: 0.72-0.86) and two or more types (OR = 0.82, 95% CI: 0.68-0.98) anti-glaucoma medicine prescriptions were less frequent in crash-involved drivers than in controls. One type (OR = 0.99, 95% CI: 0.88-1.12) and two or more types (OR = 1.04, 95% CI: 0.82-1.33) anti-glaucoma medicine prescriptions were not associated with crash responsibility.
CONCLUSION
Our findings are reassuring as regard to existing guidelines for safe driving for individuals using anti-glaucoma medications. Our results also suggest that driving behavior adaptation is effective mitigating potential traffic crash risks for people diagnosed with glaucoma.
Substances chimiques
Antiglaucoma Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
535-544Informations de copyright
© 2022 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.
Références
United Nations DoE, Affairs S. World Population Ageing, 2019.
Ikpeze TC, Elfar JC. The geriatric driver: factors that influence when to stop driving. Geriatr Orthop Surg Rehab. 2016;7(2):106-109. doi:10.1177/2151458516644818
Martin A, Balding L, O'Neill D. Are the media running elderly drivers off the road? BMJ (Clinical Research Ed). 2005;330(7487):368.
Moon S, Ranchet M, Tant M, Akinwuntan AE, Devos H. Comparison of unsafe driving across medical conditions. Mayo Clin Proc. 2017;92(9):1341-1350. doi:10.1016/j.mayocp.2017.06.003
Hill LJN, Pignolo RJ, Tung EE. Assessing and counseling the older driver: a concise review for the generalist clinician. Mayo Clin Proc. 2019;94(8):1582-1588. doi:10.1016/j.mayocp.2019.03.023
Deshmukh AV, Murthy GJ, Reddy A, Murthy PR, Kattige J, Murthy VR. Older drivers and glaucoma in India: driving habits and crash risks. J Glaucoma. 2019;28(10):896-900. doi:10.1097/ijg.0000000000001333
Klein BE. Cataract surgery and motor vehicle crashes-proceed with caution. JAMA. 2002;288(7):885-886. doi:10.1001/jama.288.7.885
Swan G, Shahin M, Albert J, Herrmann J, Bowers AR. The effects of simulated acuity and contrast sensitivity impairments on detection of pedestrian hazards in a driving simulator. Transport Res F: Traffic Psychol Behav. 2019;64:213-226. doi:10.1016/j.trf.2019.05.003
Anstey KJ, Horswill MS, Wood JM, Hatherly C. The role of cognitive and visual abilities as predictors in the multifactorial model of driving safety. Accid Anal Prev. 2012;45:766-774. doi:10.1016/j.aap.2011.10.006
Yuki K, Asaoka R, Tsubota K. The relationship between central visual field damage and motor vehicle collisions in primary open-angle glaucoma patients. PLoS One. 2014;9(12):e115572. doi:10.1371/journal.pone.0115572
Desapriya E, Harjee R, Brubacher J, et al. Vision screening of older drivers for preventing road traffic injuries and fatalities. Cochrane Database Syst Rev. 2014;(2):Cd006252. doi:10.1002/14651858.CD006252.pub4
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267. doi:10.1136/bjo.2005.081224
Kwon M, Huisingh C, Rhodes LA, McGwin G Jr, Wood JM, Owsley C. Association between glaucoma and At-fault motor vehicle collision involvement among older drivers: a population-based study. Ophthalmology. 2016;123(1):109-116. doi:10.1016/j.ophtha.2015.08.043
Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339-e349. doi:10.1016/s2214-109x(13)70113-x
Lee SS, Black AA, Wood JM. Effect of glaucoma on eye movement patterns and laboratory-based hazard detection ability. PLoS One. 2017;12(6):e0178876. doi:10.1371/journal.pone.0178876
Kunimatsu-Sanuki S, Iwase A, Araie M, et al. The role of specific visual subfields in collisions with oncoming cars during simulated driving in patients with advanced glaucoma. Br J Ophthalmol. 2017;101(7):896-901. doi:10.1136/bjophthalmol-2016-308754
Blane A. Through the looking glass: a review of the literature investigating the impact of glaucoma on crash risk, driving performance, and driver self-regulation in older drivers. J Glaucoma. 2016;25(1):113-121. doi:10.1097/ijg.0000000000000193
Montana CL, Bhorade AM. Glaucoma and quality of life: fall and driving risk. Curr Opin Ophthalmol. 2018;29(2):135-140. doi:10.1097/icu.0000000000000455
Naredo Turrado J, Orriols L, Contrand B, et al. Chronic medical conditions and their association with crash risk and changes in driving habits: a prospective study of the GAZEL cohort. Injury Prevention. 2020;27(1):17-23. doi:10.1136/injuryprev-2019-043460
Haymes SA, Leblanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci. 2007;48(3):1149-1155. doi:10.1167/iovs.06-0886
Szlyk JP, Mahler CL, Seiple W, Edward DP, Wilensky JT. Driving performance of glaucoma patients correlates with peripheral visual field loss. J Glaucoma. 2005;14(2):145-150. doi:10.1097/01.ijg.0000151686.89162.28
Kunimatsu-Sanuki S, Iwase A, Araie M, et al. An assessment of driving fitness in patients with visual impairment to understand the elevated risk of motor vehicle accidents. BMJ Open. 2015;5(2):e006379. doi:10.1136/bmjopen-2014-006379
McGwin G Jr, Mays A, Joiner W, Decarlo DK, McNeal S, Owsley C. Is glaucoma associated with motor vehicle collision involvement and driving avoidance? Invest Ophthalmol Vis Sci. 2004;45(11):3934-3939. doi:10.1167/iovs.04-0524
Detry-Morel M. Side effects of glaucoma medications. Bul-Soc Belge D Ophtal. 2006;299:27.
Yalvaç IS, Gedikoğlu G, Karagöz Y, et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995;73(3):246-248. doi:10.1111/j.1600-0420.1995.tb00277.x
Fukuda Y, Ando S, Saito M. Risk awareness, medication adherence, and driving behavior as determined by the provision of drug information to patients. Patient Educ Couns. 2020;103(8):1574-1580. doi:10.1016/j.pec.2020.02.037
Orriols L, Delorme B, Gadegbeku B, et al. Prescription medicines and the risk of road traffic crashes: a French registry-based study. PLoS Med. 2010;7(11):e1000366. doi:10.1371/journal.pmed.1000366
Jáuregui I, Mullol J, Bartra J, et al. H1 antihistamines: psychomotor performance and driving. J Investig Allergol Clin Immunol. 2006;16(suppl 1):37-44.
Orriols L, Gbaguidi GN, Contrand B, Gadegbeku B, Lagarde E. Trends in benzodiazepine anxiolytics and z-hypnotics use among French drivers involved in road traffic crashes from 2005 to 2015: a responsibility case-control study. Inj Epidemiol. 2019;6:32. doi:10.1186/s40621-019-0209-8
Jaro MA. Probabilistic linkage of large public health data files. Stat Med. 1995;14(5-7):491-498.
IMS Health. Enquête Permanente sur la Prescription Médicale (EPPM). IMS Health; 2005.
Robertson MD, Drummer OH. Responsibility analysis: a methodology to study the effects of drugs in driving. Accid Anal Prev. 1994;26(2):243-247. doi:10.1016/0001-4575(94)90094-9
Orriols L, Luxcey A, Contrand B, et al. Road traffic crash risk associated with prescription of hydroxyzine and other sedating H1-antihistamines: a responsibility and case-crossover study. Accid Anal Prev. 2017;106:115-121. doi:10.1016/j.aap.2017.05.030
Laumon B, Gadegbeku B, Martin JL, Biecheler MB. Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ. 2005;331:1371. doi:10.1136/bmj.38648.617986.1F
Orriols L, Luxcey A, Contrand B, et al. Road traffic crash risk associated with benzodiazepine and z-hypnotic use after implementation of a colour-graded pictogram: a responsibility study. Just case-control analysis and maybe the same population with other studies. There are four periods based on the implement of colour-graded three-level pictogram. Br J Clin Pharmacol. 2016;82(6):1625-1635. doi:10.1111/bcp.13075
Orriols L, Avalos-Fernandez M, Moore N, et al. Long-term chronic diseases and crash responsibility: a record linkage study. Accid Anal Prev. 2014;71:137-143. doi:10.1016/j.aap.2014.05.001
Trouessin G, Allaert FA. FOIN: a nominative information occultation function. Stud Health Technol Inform. 1997;43 Pt B:786-790.
Hu PS, Trumble DA, Foley DJ, Eberhard JW, Wallace RB. Crash risks of older drivers: a panel data analysis. Accid Anal Prev. 1998;30(5):569-581. doi:10.1016/s0001-4575(98)00019-0
Owsley C, McGwin G Jr, Ball K. Vision impairment, eye disease, and injurious motor vehicle crashes in the elderly. Ophthalmic Epidemiol. 1998;5(2):101-113. doi:10.1076/opep.5.2.101.1574
McGwin G Jr, Xie A, Mays A, et al. Visual field defects and the risk of motor vehicle collisions among patients with glaucoma. Invest Ophthalmol Vis Sci. 2005;46(12):4437-4441. doi:10.1167/iovs.05-0750
Cross JM, McGwin G Jr, Rubin GS, et al. Visual and medical risk factors for motor vehicle collision involvement among older drivers. Br J Ophthalmol. 2009;93(3):400-404. doi:10.1136/bjo.2008.144584
Owsley C, Stalvey BT, Wells J, Sloane ME, McGwin G Jr. Visual risk factors for crash involvement in older drivers with cataract. Arch Ophthalmol. 2001;119(6):881-887. doi:10.1001/archopht.119.6.881
McGwin G Jr, Huisingh C, Jain SG, Girkin CA, Owsley C. Binocular visual field impairment in glaucoma and at-fault motor vehicle collisions. J Glaucoma. 2015;24(2):138-143. doi:10.1097/IJG.0b013e3182a0761c
Ono T, Yuki K, Awano-Tanabe S, et al. Driving self-restriction and motor vehicle collision occurrence in glaucoma. Optometry Vis Sci. 2015;92(3):357-364. doi:10.1097/opx.0000000000000493
Sandlin D, McGwin G Jr, Owsley C. Association between vision impairment and driving exposure in older adults aged 70 years and over: a population-based examination. Acta Ophthalmol. 2014;92(3):e207-e212. doi:10.1111/aos.12050
Szlyk JP, Seiple W, Viana M. Relative effects of age and compromised vision on driving performance. Hum Factors. 1995;37(2):430-436. doi:10.1518/001872095779064645
Delcourt C, Korobelnik JF, Barberger-Gateau P, et al. Nutrition and age-related eye diseases: the Alienor (Antioxydants, Lipides Essentiels, nutrition et maladies OculaiRes) study. J Nutr Health Aging. 2010;14(10):854-861. doi:10.1007/s12603-010-0131-9
Nee M, Avalos M, Luxcey A, et al. Prescription medicine use by pedestrians and the risk of injurious road traffic crashes: a case-crossover study. Case crossover study. PLoS Med. 2017;14(7):e1002347. doi:10.1371/journal.pmed.1002347